company background image
FBIO

Fortress Biotech NasdaqCM:FBIO Stock Report

Last Price

US$0.85

Market Cap

US$92.0m

7D

9.4%

1Y

-72.5%

Updated

03 Oct, 2022

Data

Company Financials +
FBIO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

FBIO Stock Overview

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products.

Fortress Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fortress Biotech
Historical stock prices
Current Share PriceUS$0.85
52 Week HighUS$3.69
52 Week LowUS$0.75
Beta1.99
1 Month Change-20.22%
3 Month Change2.47%
1 Year Change-72.47%
3 Year Change-36.30%
5 Year Change-81.92%
Change since IPO-92.24%

Recent News & Updates

Aug 11

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Fortress Biotech (NASDAQ:FBIO) said that its cytomegalovirus (CMV) vaccine Triplex received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) which could provide over $20M in non-dilutive funding. The award by NIAID, part of the National Institutes of Health (NIH) will fund a phase 2 trial of Triplex —  being developed by Fortress' unit Helocyte — for control of CMV in patients undergoing liver transplantation. CMV is a common virus which is asymptomatic in healthy individuals, but can cause infection in pregnant women who then can pass the virus to their babies. CMV can be severe and life-threatening for those with weakened immune systems and those undergoing cell and solid organ transplant. Helocyte secured an exclusive worldwide license to Triplex in 2015 from City of Hope, the developer of the vaccine. Helocyte's other CMV vaccine ConVax is aimed to prevent transmission of CMV, particularly from mother to fetus, Fortress noted.

Jul 22

David Jin is the new finance chief of Fortress Biotech

Fortress Biotech (NASDAQ:FBIO) appoints David Jin as CFO succeeding Robyn Hunter, effective August 16, 2022 and will also continue to serve as Head of Corporate Development. Ms. Hunter will step down from the company after 11 years with the company to pursue external opportunities. Mr. Jin has been a core member of the Fortress team since joining in 2020 and also serves as Interim Chief Executive Officer and Chief Financial Officer of Avenue Therapeutics (ATXI), a Fortress partner company.

Shareholder Returns

FBIOUS BiotechsUS Market
7D9.4%0.4%-2.5%
1Y-72.5%-25.6%-23.2%

Return vs Industry: FBIO underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: FBIO underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is FBIO's price volatile compared to industry and market?
FBIO volatility
FBIO Average Weekly Movement11.1%
Biotechs Industry Average Movement11.1%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: FBIO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: FBIO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2006173Lindsay Rosenwaldhttps://www.fortressbiotech.com

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children.

Fortress Biotech Fundamentals Summary

How do Fortress Biotech's earnings and revenue compare to its market cap?
FBIO fundamental statistics
Market CapUS$91.96m
Earnings (TTM)-US$89.46m
Revenue (TTM)US$82.17m

1.1x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FBIO income statement (TTM)
RevenueUS$82.17m
Cost of RevenueUS$148.19m
Gross Profit-US$66.02m
Other ExpensesUS$23.44m
Earnings-US$89.46m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.83
Gross Margin-80.34%
Net Profit Margin-108.87%
Debt/Equity Ratio65.6%

How did FBIO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is FBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FBIO?

Other financial metrics that can be useful for relative valuation.

FBIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.4x
Enterprise Value/EBITDA-0.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does FBIO's PS Ratio compare to its peers?

FBIO PS Ratio vs Peers
The above table shows the PS ratio for FBIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average9.6x
XBIT XBiotech
9.8xn/aUS$108.4m
ORTX Orchard Therapeutics
5.4x44.3%US$62.6m
FIXX Homology Medicines
21.9x71.6%US$92.4m
CTMX CytomX Therapeutics
1.4x-5.9%US$95.6m
FBIO Fortress Biotech
1.1x36.6%US$92.7m

Price-To-Sales vs Peers: FBIO is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (9.6x).


Price to Earnings Ratio vs Industry

How does FBIO's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: FBIO is good value based on its Price-To-Sales Ratio (1.1x) compared to the US Biotechs industry average (13.2x)


Price to Sales Ratio vs Fair Ratio

What is FBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FBIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ratio1.5x

Price-To-Sales vs Fair Ratio: FBIO is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).


Share Price vs Fair Value

What is the Fair Price of FBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FBIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FBIO's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Fortress Biotech forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


65.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FBIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: FBIO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FBIO is expected to become profitable in the next 3 years.

Revenue vs Market: FBIO's revenue (36.6% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: FBIO's revenue (36.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FBIO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Fortress Biotech performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


3.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: FBIO is currently unprofitable.

Growing Profit Margin: FBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 3% per year.

Accelerating Growth: Unable to compare FBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: FBIO has a negative Return on Equity (-147.44%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Fortress Biotech's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: FBIO's short term assets ($299.0M) exceed its short term liabilities ($104.9M).

Long Term Liabilities: FBIO's short term assets ($299.0M) exceed its long term liabilities ($111.3M).


Debt to Equity History and Analysis

Debt Level: FBIO has more cash than its total debt.

Reducing Debt: FBIO's debt to equity ratio has increased from 31.4% to 65.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: FBIO has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 15% each year.


Discover healthy companies

Dividend

What is Fortress Biotech current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Fortress Biotech Dividend Yield vs Market
How does Fortress Biotech dividend yield compare to the market?
SegmentDividend Yield
Company (Fortress Biotech)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Fortress Biotech)n/a

Notable Dividend: Unable to evaluate FBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FBIO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as FBIO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.7yrs

Average management tenure


CEO

Lindsay Rosenwald (67 yo)

13yrs

Tenure

US$3,358,829

Compensation

Dr. Lindsay Allan Rosenwald, M.D., serves as Director at Caelum Biosciences, Inc. He serves as an Executive Chairman of Journey Medical Corporation since October 2014. He serves as an Executive Chairman of...


CEO Compensation Analysis

Lindsay Rosenwald's Compensation vs Fortress Biotech Earnings
How has Lindsay Rosenwald's remuneration changed compared to Fortress Biotech's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$89m

Mar 31 2022n/an/a

-US$72m

Dec 31 2021US$3mUS$60k

-US$65m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021n/an/a

-US$33m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$3mUS$59k

-US$47m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$54m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$1mUS$32k

-US$40m

Sep 30 2019n/an/a

-US$45m

Jun 30 2019n/an/a

-US$51m

Mar 31 2019n/an/a

-US$53m

Dec 31 2018US$2mUS$31k

-US$73m

Sep 30 2018n/an/a

-US$61m

Jun 30 2018n/an/a

-US$69m

Mar 31 2018n/an/a

-US$72m

Dec 31 2017US$2mUS$31k

-US$65m

Sep 30 2017n/an/a

-US$74m

Jun 30 2017n/an/a

-US$60m

Mar 31 2017n/an/a

-US$55m

Dec 31 2016US$2mUS$30k

-US$55m

Sep 30 2016n/an/a

-US$50m

Jun 30 2016n/an/a

-US$55m

Mar 31 2016n/an/a

-US$49m

Dec 31 2015US$3mUS$28k

-US$48m

Compensation vs Market: Lindsay's total compensation ($USD3.36M) is above average for companies of similar size in the US market ($USD781.86K).

Compensation vs Earnings: Lindsay's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: FBIO's management team is seasoned and experienced (8.7 years average tenure).


Board Members

Experienced Board: FBIO's board of directors are considered experienced (8.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqCM:FBIO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 Dec 21SellUS$12,250Dov KleinIndividual5,000US$2.45

Ownership Breakdown

What is the ownership structure of FBIO?
Owner TypeNumber of SharesOwnership Percentage
Hedge Funds8,758,6488.1%
Institutions25,148,09323.3%
Individual Insiders28,270,09226.2%
General Public45,557,98842.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.5%.


Top Shareholders

Top 25 shareholders own 55.17% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.45%
Michael Weiss
12,335,136$10.5m0%no data
11.36%
Lindsay Rosenwald
12,236,285$10.4m0%no data
8.13%
Nantahala Capital Management, LLC
8,758,648$7.5m-0.95%0.68%
4.76%
The Vanguard Group, Inc.
5,131,708$4.4m-9.57%no data
3.1%
Tang Capital Management, LLC
3,342,801$2.9m42.25%0.41%
3.01%
Opaleye Management Inc.
3,247,180$2.8m-13.41%1.08%
1.6%
Medical Strategy GmbH, Asset Management Arm
1,724,242$1.5m3.23%0.1%
1.31%
BlackRock, Inc.
1,415,830$1.2m-69.99%no data
1.15%
J. Lobell
1,236,000$1.1m0%no data
0.91%
Oasis Management Company Ltd.
985,222$841.0k0%0.07%
0.81%
Millennium Management LLC
876,193$747.9k569.93%no data
0.74%
Shikiar Asset Management Inc.
800,000$682.9k11.46%0.3%
0.73%
CPWM, LLC
781,767$667.3k18.04%0.06%
0.71%
Perkins Capital Management, Inc.
760,992$649.6k640.23%0.75%
0.69%
Paramount BioSciences, LLC
742,861$634.1k0%100%
0.67%
Eric Rowinsky
720,000$614.6k0%no data
0.63%
Acadian Asset Management LLC
680,563$580.9k60.25%no data
0.63%
Geode Capital Management, LLC
677,518$578.3k-46.74%no data
0.61%
George Avgerinos
655,170$559.3k0%no data
0.52%
Renaissance Technologies LLC
565,100$482.4k-48.69%no data
0.52%
Foord Asset Management (Guernsey) Limited
558,000$476.3k0%0.04%
0.32%
Ergoteles LLC
344,300$293.9k0%0.01%
0.29%
State Street Global Advisors, Inc.
316,377$270.1k-75.53%no data
0.25%
Kevin Lorenz
274,572$234.4k0%no data
0.25%
Kevin Lorenz
274,572$234.4k0%no data

Company Information

Fortress Biotech, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Fortress Biotech, Inc.
  • Ticker: FBIO
  • Exchange: NasdaqCM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$91.962m
  • Shares outstanding: 107.73m
  • Website: https://www.fortressbiotech.com

Number of Employees


Location

  • Fortress Biotech, Inc.
  • 1111 Kane Concourse
  • Suite 301
  • Bay Harbor Islands
  • Florida
  • 33154
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FBIONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2011
CNBDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2011
FBIO.PNasdaqCM (Nasdaq Capital Market)9.375% CUM RED PER PREF SER A USD25.00USUSDNov 2017
CNB0DB (Deutsche Boerse AG)9.375% CUM RED PER PREF SER A USD25.00DEEURNov 2017

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.